Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges

Author： Rosenbaum Eli   Carducci Michael A  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.4, Iss.6, 2003-06, pp. : 875-887

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Which drug combination for hormone-refractory prostate cancer?

By Doggrell Sheila A  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 4, 2005-04 ,pp. : 667-670

Informa Healthcare

Access to resources Recommend Favorite

Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 6, 2013-05 ,pp. : 915-920

Bentham Science Publishers

Access to resources Recommend Favorite

Docetaxel: In Hormone-Refractory Metastatic Prostate Cancer

By McKeage Kate   Keam Susan J.  

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2287-2294

Adis International

Access to resources Recommend Favorite

Docetaxel in Hormone-Refractory Metastatic Prostate Cancer: A Viewpoint by William R. Berry

By Berry William R.  

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2295-2297

Adis International

Access to resources Recommend Favorite

Treatment Options in Hormone-Refractory Prostate Cancer: Current and Future Approaches

By Harris K.A.   Reese D.M.  

Drugs, Vol. 61, Iss. 15, 2001-01 ,pp. : 2177-2192

Adis International

Access to resources Recommend Favorite